Press Releases

September 30, 2022

Non Regulatory

SynAct Pharma submits IND for US Phase 2a/b clinical trial

September 27, 2022

Non Regulatory

SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA

September 14, 2022

Non Regulatory

Approval of amended study protocol for the Phase 2a study in iMN

August 25, 2022

Non Regulatory

CTA approved for the Phase 2b study EXPAND

August 16, 2022

Non Regulatory

Resomelagon proposed international nonproprietary name (INN) for AP1189

August 5, 2022

Regulatory

SynAct Pharma publishes Q2 2022 interim report

July 21, 2022

Non Regulatory

SynAct Pharma improves the design of the ongoing Phase 2a study in iMN

July 12, 2022

Regulatory

Trading in SynAct Pharma’s shares on Nasdaq Stockholm commences today

July 8, 2022

Regulatory

SynAct Pharma AB publishes prospectus for list change to Nasdaq Stockholm

June 29, 2022

Regulatory

SynAct Pharma recieves pre-IND response from the US FDA

June 28, 2022

Regulatory

SynAct Pharma AB has been approved for listing on Nasdaq Stockholm

June 21, 2022

Non Regulatory

SynAct Pharma submits CTA for Clinical Phase 2b Study in RA

May 30, 2022

Regulatory

SynAct Pharma publishes Q1 2022 interim report

May 20, 2022

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022

May 18, 2022

Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 12, 2022

Regulatory

Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB

May 4, 2022

Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 29, 2022

Regulatory

SynAct Pharma AB publishes Annual Report 2021

April 25, 2022

Regulatory

SynAct announces outcome of rights issue

April 20, 2022

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 1, 2022

Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

March 28, 2022

Regulatory

Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB

March 28, 2022

Regulatory

SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million

March 9, 2022

Regulatory

Notice of extraordinary general meeting in SynAct Pharma AB

March 9, 2022

Regulatory

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

February 11, 2022

Regulatory

Annual Results 2021

January 7, 2022

Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO